Table 5.
ALK mutations and their impact on the efficiency of ALK inhibitors
| ALK mutation | Poorly effective | Effective | Highly effective | Reference |
|---|---|---|---|---|
| G1123S | Ceritinib | [118] | ||
| G1128A | Crizotinib, Ceritinib | Brigatinib, Lorlatinib, Alectinib | [119, 120] | |
| L1151Tins | Crizotinib | [118] | ||
| L1152R | Crizotinib | [118] | ||
| C1156Y | Crizotinib | [118] | ||
| I1171N | Crizotinib | Ceritinib | Brigatinib, Lorlatinib, Alectinib | [118–120] |
| I1171T | Crizotinib, Alectinib | Ceritinib | Brigatinib, Lorlatinib, Alectinib | [119, 120] |
| F1174C | Ceritinib | [121] | ||
| F1174L | Crizotinib (partial inhibition) | Ceritinib | Brigatinib, Lorlatinib, Alectinib | [118–121] |
| F1174V | Crizotinib, Ceritinib | [118] | ||
| R1192P | Crizotinib, Ceritinib | Brigatinib, Lorlatinib, Alectinib | [119, 120] | |
| L1196M | Crizotinib | [118] | ||
| L1198F | Lorlatinib | [118] | ||
| G1202R | Crizotinib, Ceritinib, Alectinib | [118] | ||
| S1206Y | Crizotinib | [118] | ||
| F1245V | Crizotinib, Ceritinib | Brigatinib, Lorlatinib | [119, 121] | |
| F1245C | Crizotinib | Alectinib | [118, 120] | |
| G1269A | Crizotinib | Ceritinib | Brigatinib, Lorlatinib, Alectinib | [118–120] |
| R1275Q | Crizotinib, Ceritinib | Brigatinib, Lorlatinib, Alectinib | [117, 119, 120] | |
| Y1278S | Crizotinib, Ceritinib | Brigatinib, Lorlatinib, Alectinib | [119, 120] |